company background image
DPHARMA logo

Duopharma Biotech Berhad KLSE:DPHARMA Stock Report

Last Price

RM1.24

Market Cap

RM1.2b

7D

-0.8%

1Y

-8.1%

Updated

14 Jun, 2024

Data

Company Financials +

Duopharma Biotech Berhad

KLSE:DPHARMA Stock Report

Market Cap: RM1.2b

DPHARMA Stock Overview

An investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally.

DPHARMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance2/6
Financial Health3/6
Dividends3/6

Duopharma Biotech Berhad Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Duopharma Biotech Berhad
Historical stock prices
Current Share PriceRM1.24
52 Week HighRM1.35
52 Week LowRM1.11
Beta0.59
1 Month Change2.48%
3 Month Change2.48%
1 Year Change-8.15%
3 Year Change-47.51%
5 Year Change22.47%
Change since IPO207.51%

Recent News & Updates

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17
Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07
Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28
Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27
Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26
We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25
Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 14
A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12
Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Jan 28
Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Shareholder Returns

DPHARMAMY PharmaceuticalsMY Market
7D-0.8%0.6%1.1%
1Y-8.1%4.7%21.4%

Return vs Industry: DPHARMA underperformed the MY Pharmaceuticals industry which returned 4.7% over the past year.

Return vs Market: DPHARMA underperformed the MY Market which returned 21.4% over the past year.

Price Volatility

Is DPHARMA's price volatile compared to industry and market?
DPHARMA volatility
DPHARMA Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement5.4%
10% most volatile stocks in MY Market11.5%
10% least volatile stocks in MY Market2.6%

Stable Share Price: DPHARMA has not had significant price volatility in the past 3 months.

Volatility Over Time: DPHARMA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19781,650Leonard bin Abdul Shatarduopharmabiotech.com

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others.

Duopharma Biotech Berhad Fundamentals Summary

How do Duopharma Biotech Berhad's earnings and revenue compare to its market cap?
DPHARMA fundamental statistics
Market capRM1.20b
Earnings (TTM)RM45.29m
Revenue (TTM)RM697.22m

26.3x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DPHARMA income statement (TTM)
RevenueRM697.22m
Cost of RevenueRM437.16m
Gross ProfitRM260.06m
Other ExpensesRM214.77m
EarningsRM45.29m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.047
Gross Margin37.30%
Net Profit Margin6.50%
Debt/Equity Ratio77.5%

How did DPHARMA perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

49%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.